Investment analysts at Goldman Sachs Group began coverage on shares of Precision BioSciences (NASDAQ:DTIL) in a research report issued on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $24.00 price target on the stock. Goldman Sachs Group’s target price suggests a potential upside of 76.73% from the stock’s previous close.
Separately, Barclays began coverage on shares of Precision BioSciences in a research note on Monday. They issued an “overweight” rating and a $24.00 target price on the stock.
NASDAQ:DTIL opened at $13.58 on Monday. Precision BioSciences has a 52-week low of $12.13 and a 52-week high of $19.00.
In other Precision BioSciences news, Director Global Strategic Fund Venbio bought 50,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were acquired at an average price of $16.00 per share, with a total value of $800,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Tony Dung Ling Yao bought 6,487 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The stock was acquired at an average cost of $15.42 per share, for a total transaction of $100,029.54. The disclosure for this purchase can be found here.
Precision BioSciences Company Profile
Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.
Recommended Story: How Do You Make Money With Penny Stocks?
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.